Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084905/
https://www.ncbi.nlm.nih.gov/pubmed/35547599
http://dx.doi.org/10.2147/CMAR.S372533
_version_ 1784703701674360832
collection PubMed
description
format Online
Article
Text
id pubmed-9084905
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90849052022-05-10 Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum] Cancer Manag Res Corrigendum Dove 2022-05-05 /pmc/articles/PMC9084905/ /pubmed/35547599 http://dx.doi.org/10.2147/CMAR.S372533 Text en © 2022 Tong et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Corrigendum
Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]
title Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]
title_full Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]
title_fullStr Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]
title_full_unstemmed Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]
title_short Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]
title_sort baseline serum cholesterol levels predict the response of patients with advanced non-small cell lung cancer to immune checkpoint inhibitor-based treatment [corrigendum]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084905/
https://www.ncbi.nlm.nih.gov/pubmed/35547599
http://dx.doi.org/10.2147/CMAR.S372533

Ejemplares similares